financetom
CC
financetom
/
Materials
/
CC
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
The Chemours CompanyCC
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.

It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.

The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents.

The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and other applications.

The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors.

The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.

Latest News >
Satellos Files IND to Start Phase 2 U.S. Trial of SAT-3247 for Duchenne Muscular Dystrophy
Satellos Files IND to Start Phase 2 U.S. Trial of SAT-3247 for Duchenne Muscular Dystrophy
Sep 22, 2025
07:40 AM EDT, 09/22/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) Monday said it has submitted an Investigational New Drug (IND) application to the U.S. FDA to initiate a Phase 2 clinical trial of its lead compound SAT-3247 in children with Duchenne muscular dystrophy (DMD). The company is also filing applications to the U.K., Europe, Serbia and Australia. The...
Steakholder Foods to Acquire Twine Solutions;  Shares Gain Pre-Bell
Steakholder Foods to Acquire Twine Solutions; Shares Gain Pre-Bell
Sep 22, 2025
07:39 AM EDT, 09/22/2025 (MT Newswires) -- Steakholder Foods ( STKH ) said Monday it has signed an agreement to acquire Twine Solutions through an equity transaction. The company said that Twine's shareholders will receive a minority stake in Steakholder Foods ( STKH ) in return for all outstanding shares of Twine on a fully-diluted basis. This stake will include...
AstraZeneca's Koselugo Recommended for Approval in EU to Treat Neurofibromatosis Type 1
AstraZeneca's Koselugo Recommended for Approval in EU to Treat Neurofibromatosis Type 1
Sep 22, 2025
07:41 AM EDT, 09/22/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Koselugo in the European Union to treat neurofibromatosis type 1. The UK pharmaceutical company said the decision was based on a phase 3 trial that showed a statistically significant objective response...
Bristol Myers plans UK launch of schizophrenia drug in 2026
Bristol Myers plans UK launch of schizophrenia drug in 2026
Sep 22, 2025
Sept 22 (Reuters) - Bristol Myers Squibb ( BMY ) said on Monday that it was planning to launch its schizophrenia treatment, Cobenfy, in the UK in 2026 and that the pricing would be similar to its U.S. list price. The drug carries a list price of $1,850 a month or about $22,500 annually in the United States. Bristol said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved